|
|
|
|
| LEADER |
03038nam a2200337 u 4500 |
| 001 |
EB002002134 |
| 003 |
EBX01000000000000001165035 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Ertugliflozin (Steglatro) (Merck Canada Inc.)
|h Elektronische Ressource
|b indication : type 2 diabetes mellitus
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Steglatro
|
| 246 |
3 |
1 |
|a Ertugliflozin (Steglatro) (Merck Canada Inc.)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c February 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (14 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / economics
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / economics
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK542500
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Ertugliflozin is an oral antidiabetic drug belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) for whom metformin is inappropriate due to contraindications or intolerance; and adjunct to diet and exercise to improve glycemic control in adult patients with T2DM inadequately controlled on metformin alone or metformin and sitagliptin. The manufacturer is seeking reimbursement as monotherapy for patients with T2DM who have inadequate glycemic control and for whom metformin or a sulfonylurea is inappropriate due to contraindications or intolerances, and as an add-on therapy to metformin in patients who have inadequate glycemic control and have a contraindication or intolerance to sulfonylurea. The recommended starting dose of ertugliflozin is 5 mg, taken once daily in the morning with or without food. The daily dose may be increased to a maximum of 15 mg if additional glycemic control is needed. The manufacturer submitted ertugliflozin at a price of $2.45 per tablet for both 5 mg and 15 mg doses, or an annual cost of $894 per patient. CADTH Common Drug Review (CDR) is currently reviewing ertugliflozin as part of a fixed-dose combination with metformin which is indicated as an adjunct to diet and exercise alone, or in combination with sitagliptin, for those patients with T2DM who are inadequately controlled on metformin, or metformin and sitagliptin; or for patients who are on the individual components (ertugliflozin and metformin)
|